ADORA2A and neoplasm: Furthermore, targeting A2AR via CRISPR/Cas9-mediated editing is applicable to CAR T-cell therapy in multiple tumor types where adenosine signaling has been shown to suppress anti-tumor immunity, including breast cancer, ovarian cancer, lung cancer, acute myeloid leukemia, multiple myeloma, and non-Hodgkin’s lymphoma21–25.